### Introduction

- **Objective:** To evaluate the efficacy and safety of EXE+HER2 in patients with HER2+ advanced BC progressing after NSAI therapy.
- **Methods:** Study design, patient selection, and trial endpoints.

### Results

#### Baseline Patient Demographics and Disease Characteristics

<table>
<thead>
<tr>
<th>Disease Status</th>
<th>Missing</th>
<th>%</th>
<th>% (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic</td>
<td>906</td>
<td>68.7</td>
<td>62.7-75.1</td>
</tr>
<tr>
<td>Locally Advanced</td>
<td>410</td>
<td>31.3</td>
<td>27.6-35.6</td>
</tr>
<tr>
<td>Missing</td>
<td>400</td>
<td>29.7</td>
<td>27.6-35.6</td>
</tr>
</tbody>
</table>

#### Median OS Duration

- **All Patients:** 15.3 months
- **HER2+ Patients:** 15.3 months

#### Safety Set (N = 299)

- **Adverse Events:**
  - **Grade 3 or 4:**
    - **Nausea:** 36 (12.1%)
    - **Diarrhea:** 20 (6.7%)
    - **Vomiting:** 19 (6.4%)
    - **Weight Decreased:** 14 (4.7%)
    - **Dyspnea:** 10 (3.4%)
    - **Nausea:** 9 (3.0%)
    - **Fatigue:** 9 (3.0%)
    - **Vomiting:** 5 (1.7%)
    - **Hypokalemia:** 5 (1.7%)
    - **General Physical Health Deterioration:** 5 (1.7%)

#### Overall Response Rate (ORR)

- **All Patients:** 11.5% (95% CI 6.6-18.3%)
- **HER2+ Patients:** 11.5% (95% CI 6.6-18.3%)
- **HER2- Patients:** 11.5% (95% CI 6.6-18.3%)
- **HER2- Patients (prior chemotherapy):** 6.6% (95% CI 3.2-11.8%)

#### Progression-Free Survival (PFS)

- **All Patients:** 5.6 months (95% CI 5.4-6.0 months)
- **HER2+ Patients:** 5.6 months (95% CI 5.4-6.0 months)
- **HER2- Patients:** 5.6 months (95% CI 5.4-6.0 months)
- **HER2- Patients (prior chemotherapy):** 5.6 months (95% CI 5.4-6.0 months)

#### Summary

- EXE+HER2 demonstrated a clinically meaningful ORR and PFS in patients with HER2+ advanced BC.
- The treatment was well-tolerated, with a manageable safety profile.

### Discussion

- The results highlight the potential of EXE+HER2 in HER2+ advanced BC.
- Further studies are needed to confirm these findings.

### Acknowledgments

- The authors thank the patients and their families for their participation and support.
- Funding and support from Novartis Pharma AG are gratefully acknowledged.

### References


#### Abbreviations:

- **CI:** Confidence interval
- **HER2:** Human epidermal growth factor receptor 2
- **OS:** Overall survival
- **ORR:** Overall response rate
- **NSAI:** Nonsteroidal aromatase inhibitor
- **PFS:** Progression-free survival

---

*Presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 11-14, 2023, San Antonio, TX, USA.*